dipyridamole has been researched along with Mucositis, Oral in 2 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "7 mg/kg/d of dipyridamole, we examined the relationships between 5FUra dose and steady-state plasma concentration (Css) and the percentage reduction in WBCs, as well as the percentage frequency of stomatitis." | 3.68 | Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. ( Egorin, MJ; Forrest, A; Remick, S; Trump, DL; Tutsch, KD; Willson, JK, 1991) |
| "Stomatitis was observed in 44/78 (56%) courses." | 2.67 | A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. ( Alberti, D; Arzoomanian, RZ; Bailey, H; Grem, JL; Spriggs, DR; Tombes, MB; Tutsch, KD; Wilding, G, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, H | 1 |
| Wilding, G | 1 |
| Tutsch, KD | 2 |
| Arzoomanian, RZ | 1 |
| Alberti, D | 1 |
| Tombes, MB | 1 |
| Grem, JL | 1 |
| Spriggs, DR | 1 |
| Trump, DL | 1 |
| Egorin, MJ | 1 |
| Forrest, A | 1 |
| Willson, JK | 1 |
| Remick, S | 1 |
1 trial available for dipyridamole and Mucositis, Oral
| Article | Year |
|---|---|
A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Dose-Response Relationshi | 1992 |
1 other study available for dipyridamole and Mucositis, Oral
| Article | Year |
|---|---|
Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.
Topics: Bone Marrow Diseases; Dipyridamole; Dose-Response Relationship, Drug; Drug Interactions; Fluorouraci | 1991 |